What is the 13F Pro Quality Score for VIR?

13F Pro ranks Vir Biotechnology, Inc. (VIR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VIR's current score at https://13fpro.ai/company/VIR (free sign-up required for the full ranking).

Where does 13F Pro source VIR data?

All Vir Biotechnology, Inc. fundamentals and ownership data come directly from SEC EDGAR. Vir Biotechnology, Inc. files with the SEC under CIK 1706431. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VIR in?

Vir Biotechnology, Inc. (VIR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VIR research updated on 13F Pro?

VIR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vir Biotechnology, Inc.(VIR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1706431 VIR stock profile & AI dashboard →

13F Pro Quality Score

38.2/100

Rank #2,208 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

97.6/100

Profitability

8.4/100

Balance Sheet

10.7/100

Earnings Quality

21.3/100

Free Cash Flow

7.9/100

Institutional Flow

74.4/100

Revenue Scale

29.6/100

Dilution Risk

3.8/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why VIR Scores 38/100

exact factor attribution · 2026-09-11

VIR's composite is driven by revenue growth and earnings growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+9.5 pts

98th pct

Earnings growth

+2.2 pts

94th pct

Institutional flow

+1.2 pts

74th pct

Shareholder dilution

-2.3 pts

4th pct

Earnings quality

-2.9 pts

21th pct

Scale

-3.1 pts

30th pct

Capital efficiency

-3.9 pts

11th pct

Profitability

-6.2 pts

8th pct

Free cash flow

-6.3 pts

8th pct

Latest change (2026-08-06): 6 → 7 · ↑ Capital efficiency 3→12

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

VIR Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Vir Biotechnology, Inc. (VIR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VIR at 38.2/100 on a 32-signal composite quality model, placing it at rank #2,208 of 2,962 stocks — the bottom half of the AI-ranked universe. VIR scores in the top quartile across revenue growth (97.6). Areas of concern include free cash flow (7.9) and profitability (8.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Vir Biotechnology, Inc. reports quarterly revenue of $238.9M, net income of $80.1M, free cash flow of $123.3M. Top institutional holders of VIR by reported 13-F value include BlackRock, ARCH Venture Management, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. VIR trades on the Nasdaq exchange and files with the SEC under CIK 1706431. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VIR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vir Biotechnology, Inc. directly from SEC EDGAR. Vir Biotechnology, Inc.'s 13F Pro composite quality score has ranged between 7 and 84 since 2021, currently 38.2 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$238.9M

Net Income

Q2 2026

$80.1M

Free Cash Flow

Q2 2026

$123.3M

ROIC

Q2 2026

29.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-7.6% YoY

$68.6MFY 2025

FY22 $1.62BFY23 $86.2MFY24 $74.2MFY25 $68.6M

Net Income

+16.1% YoY

$-438.0MFY 2025

FY22 $515.8MFY23 $-615.1MFY24 $-522.0MFY25 $-438.0M

Operating Income

+18.4% YoY

$-479.3MFY 2025

FY22 $833.1MFY23 $-684.3MFY24 $-587.2MFY25 $-479.3M

EPS (Diluted)

+17.5% YoY

$-3.16FY 2025

FY22 $3.83FY23 $-4.59FY24 $-3.83FY25 $-3.16

Total Assets

-28.3% YoY

$1.00BFY 2025

FY22 $2.80BFY23 $1.92BFY24 $1.40BFY25 $1.00B

Op. Cash Flow

+12.2% YoY

$-391.8MFY 2025

FY22 $1.66BFY23 $-778.8MFY24 $-446.4MFY25 $-391.8M

Free Cash Flow

+12.6% YoY

$-396.6MFY 2025

FY22 $1.60BFY23 $-800.4MFY24 $-453.7MFY25 $-396.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$68.6M -7.6%	$74.2M -13.9%	$86.2M -94.7%	$1.62B +47.5%	$1.10B +1334.4%	$76.4M
Net Income	$-438.0M +16.1%	$-522.0M +15.1%	$-615.1M -219.2%	$515.8M -2.4%	$528.6M +277.0%	$-298.7M
Operating Income	$-479.3M +18.4%	$-587.2M +14.2%	$-684.3M -182.1%	$833.1M +98.0%	$420.8M +241.7%	$-297.0M
EPS (Diluted)	$-3.16 +17.5%	$-3.83 +16.6%	$-4.59 -219.8%	$3.83 -3.3%	$3.96 +257.8%	$-2.51
Total Assets	$1.00B -28.3%	$1.40B -27.1%	$1.92B -31.5%	$2.80B +43.4%	$1.95B +112.7%	$918.8M
Operating Cash Flow	$-391.8M +12.2%	$-446.4M +42.7%	$-778.8M -146.8%	$1.66B +3595.0%	$-47.6M +75.1%	$-190.9M
Free Cash Flow	$-396.6M +12.6%	$-453.7M +43.3%	$-800.4M -150.2%	$1.60B +2398.4%	$-69.4M +64.9%	$-197.5M

Get alerted when VIR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vir Biotechnology, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VIR

BlackRock, Inc.
$210.7M20,678,283 sh
ARCH Venture Management, LLC
$129.4M12,694,163 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$117.1M11,495,215 sh
SB INVESTMENT ADVISERS (UK) LTD
$111.6M10,948,093 sh
STATE STREET CORP
$101.5M9,964,151 sh
GSK plc
$87.1M8,550,954 sh
VANGUARD CAPITAL MANAGEMENT LLC
$65.1M6,388,775 sh
Point72 Asset Management, L.P.
$57.7M5,666,821 sh
GEODE CAPITAL MANAGEMENT, LLC
$34.1M3,348,366 sh
DIMENSIONAL FUND ADVISORS LP
$31.8M3,119,421 sh

Fund	Value	Shares
BlackRock, Inc.	$210.7M	20,678,283
ARCH Venture Management, LLC	$129.4M	12,694,163
VANGUARD PORTFOLIO MANAGEMENT LLC	$117.1M	11,495,215
SB INVESTMENT ADVISERS (UK) LTD	$111.6M	10,948,093
STATE STREET CORP	$101.5M	9,964,151
GSK plc	$87.1M	8,550,954
VANGUARD CAPITAL MANAGEMENT LLC	$65.1M	6,388,775
Point72 Asset Management, L.P.	$57.7M	5,666,821
GEODE CAPITAL MANAGEMENT, LLC	$34.1M	3,348,366
DIMENSIONAL FUND ADVISORS LP	$31.8M	3,119,421

Companies Similar to VIR

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

IVVD

Invivyd, Inc.

AI score

Very similar · 9 shared holders

Saturn V Capital Management LP Soleus Capital Management, L.P.ADAR1 Capital Management, LLC

BEAM

Beam Therapeutics Inc.

AI score

Similar quality profile · 13 shared holders

ARCH Venture Management, LLC Susquehanna Portfolio Strategies, LLC Clarius Group, LLC

PHAT

Phathom Pharmaceuticals, Inc.

AI score

Similar quality profile · 7 shared holders

Avidity Partners Management LP Jones Hill Capital LP Birchview Capital, LP

IOVA

IOVANCE BIOTHERAPEUTICS, INC.

AI score

Similar quality profile · 12 shared holders

Susquehanna Portfolio Strategies, LLC Raiffeisen Bank International AG Soleus Capital Management, L.P.

TNXP

Tonix Pharmaceuticals Holding Corp.

AI score

Similar quality profile · 4 shared holders

Jones Hill Capital LP Susquehanna Portfolio Strategies, LLC SUPERSTRING CAPITAL MANAGEMENT LP

BCYC

BICYCLE THERAPEUTICS PLC

AI score

Similar quality profile · 10 shared holders

GSK plc Birchview Capital, LP Eversept Partners, LP

RGNX

REGENXBIO Inc.

AI score

Similar quality profile · 10 shared holders

GSK plc Susquehanna Portfolio Strategies, LLC ACT CAPITAL MANAGEMENT, LLC

RARE

Ultragenyx Pharmaceutical Inc.

AI score

Similar quality profile · 14 shared holders

GordonMD Global Investments LP Candriam S.C.A.Eversept Partners, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VIR on your watchlist

Track score changes the day Vir Biotechnology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VIR a good stock to buy?

13F Pro's AI-powered analysis of Vir Biotechnology, Inc. (VIR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VIR are available on the VIR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VIR is classified as a small company.

Which hedge funds own VIR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VIR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vir Biotechnology, Inc.'s investment landscape.